- Home
- CAPR vs AUTL Comparison
CAPR vs AUTL Comparison
Compare CAPR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- AUTL
- Stock Information
- Founded
- CAPR 2005
- AUTL 2014
- Country
- CAPR United States
- AUTL United Kingdom
- Employees
- CAPR N/A
- AUTL N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAPR Health Care
- AUTL Health Care
- Exchange
- CAPR Nasdaq
- AUTL Nasdaq
- Market Cap
- CAPR 324.6M
- AUTL 368.6M
- IPO Year
- CAPR N/A
- AUTL 2018
- Fundamental
- Price
- CAPR $4.66
- AUTL $1.24
- Analyst Decision
- CAPR Strong Buy
- AUTL Strong Buy
- Analyst Count
- CAPR 6
- AUTL 3
- Target Price
- CAPR $23.17
- AUTL $8.33
- AVG Volume (30 Days)
- CAPR 1.9M
- AUTL 2.2M
- Earning Date
- CAPR 11-10-2025
- AUTL 11-12-2025
- Dividend Yield
- CAPR N/A
- AUTL N/A
- EPS Growth
- CAPR N/A
- AUTL N/A
- EPS
- CAPR N/A
- AUTL N/A
- Revenue
- CAPR $11,130,509.00
- AUTL $51,128,000.00
- Revenue This Year
- CAPR N/A
- AUTL $643.50
- Revenue Next Year
- CAPR $7,894.07
- AUTL $108.69
- P/E Ratio
- CAPR N/A
- AUTL N/A
- Revenue Growth
- CAPR N/A
- AUTL 406.67
- 52 Week Low
- CAPR $4.40
- AUTL $1.11
- 52 Week High
- CAPR $20.75
- AUTL $3.45
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- AUTL 38.48
- Support Level
- CAPR $5.52
- AUTL $1.20
- Resistance Level
- CAPR $6.01
- AUTL $1.35
- Average True Range (ATR)
- CAPR 0.49
- AUTL 0.09
- MACD
- CAPR -0.06
- AUTL -0.01
- Stochastic Oscillator
- CAPR 12.42
- AUTL 10.94
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.